Literature DB >> 15184866

Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors.

Lei Wang1, Yong Pan, Jia Le Dai.   

Abstract

MKK4, located in close proximity to p53 gene, is thought to be a tumor suppressor and a metastasis suppressor gene. A low-rate MKK4 gene alteration has been found in a few tumor types, including breast and pancreatic. A suppressor activity for prostate and ovarian tumor metastasis has also been suggested. To understand the pathobiologic roles of MKK4 in tumorigenesis, we examined the phenotypic changes in response to perturbation of the MKK4 expression in breast and pancreatic cancer cell lines. Ectopic expression of MKK4 by adenoviral delivery in MKK4-negative cancer lines stimulated the cell proliferation and invasion, whereas knockdown of MKK4 expression by small interference RNA in an MKK4-positive breast cancer cell line, MDA-MB-231, resulted in decreased anchorage-independent growth, suppressed tumor growth in mouse xenograft model, and increased cell susceptibility to apoptosis brought by stress signals such as serum deprivation. These results argue that MKK4 functions as a pro-oncogenic molecule instead of a suppressor in breast and pancreatic tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184866     DOI: 10.1038/sj.onc.1207802

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

2.  MKK4 acts as a potential tumor suppressor in ovarian cancer.

Authors:  Shamima Yeasmin; Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Masako Ishikawa; Atsuko Katagiri; Kouji Iida; Naomi Nakayama; Kohji Miyazaki
Journal:  Tumour Biol       Date:  2011-04-14

3.  [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].

Authors:  Shu Liu; Yi-Yi Liu; Rong Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

4.  Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.

Authors:  Andreas M Stark; Kerrin Tongers; Nicolai Maass; H Maximilian Mehdorn; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-08       Impact factor: 4.553

5.  [Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].

Authors:  Chun-Hua Liu; Qing-Ping Jiang; Dan Lin; Wei Chen; Yan-Yi Xiao; Li Lin; Yuan-Run Deng; Hui-Ping Jiang; Sui-Qun Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

6.  Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.

Authors:  Lei Wang; Eswaran Devarajan; Jin He; Sekhar P Reddy; Jia Le Dai
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

7.  Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.

Authors:  Kristine K Deibler; Gary E Schiltz; Matthew R Clutter; Rama K Mishra; Purav P Vagadia; Matthew O'Connor; Mariam Donny George; Ryan Gordon; Graham Fowler; Raymond Bergan; Karl A Scheidt
Journal:  ChemMedChem       Date:  2019-02-19       Impact factor: 3.466

Review 8.  Inhibition of cancer cell invasion and metastasis by genistein.

Authors:  Janet M Pavese; Rebecca L Farmer; Raymond C Bergan
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

9.  Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.

Authors:  Rama K Mishra; Kristine K Deibler; Matthew R Clutter; Purav P Vagadia; Matthew O'Connor; Gary E Schiltz; Raymond Bergan; Karl A Scheidt
Journal:  J Chem Inf Model       Date:  2019-10-14       Impact factor: 4.956

10.  MEK4 function, genistein treatment, and invasion of human prostate cancer cells.

Authors:  Li Xu; Yongzeng Ding; William J Catalona; Ximing J Yang; Wayne F Anderson; Borko Jovanovic; Kenji Wellman; Jaqueline Killmer; Xiaoke Huang; Karl A Scheidt; R Bruce Montgomery; Raymond C Bergan
Journal:  J Natl Cancer Inst       Date:  2009-07-28       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.